First Light reports 5.34% stake in Palvella Therapeutics
First Light Asset Management, LLC and Mathew P. Arens report beneficial ownership of 769,117 shares of Palvella Therapeutics, Inc. common stock, representing 5.34% of the class.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
First Light Asset Management, LLC and Mathew P. Arens report beneficial ownership of 769,117 shares of Palvella Therapeutics, Inc. common stock, representing 5.34% of the class. The shares are held in separately managed accounts and private funds for which First Light serves as investment adviser.
Both reporting persons have shared voting and dispositive power over the 769,117 shares and no sole voting or dispositive power. They state that beneficial ownership is reported solely for Section 13(d) purposes and is not an admission of beneficial ownership for other purposes.
Key Figures
Key Terms
beneficial owner financial
dispositive power financial
separately managed accounts financial
private funds financial
Section 13(d) of the Securities Exchange Act of 1934 regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What percentage of Palvella Therapeutics (PVLA) does First Light Asset Management report owning?
How do First Light Asset Management and Mathew P. Arens describe their beneficial ownership of PVLA shares?
Where are the reporting persons for the Palvella Therapeutics (PVLA) stake located?
AI-generated analysis. How Rhea-AI works. Not financial advice.